Matthew Zuga compensation by year
Acumen Pharmaceuticals Summary Compensation Table · all 5 fiscal years held| Component | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Salary | $315,430 | $429,836 | $450,253 | $468,263 | $486,993 |
| Bonus | $55,000 | $0 | $0 | $0 | $0 |
| Stock awards | $0 | $0 | $204,685 | $448,380 | $123,580 |
| Option awards | $257,280 | $580,500 | $699,003 | $537,977 | $143,429 |
| Non-equity incentive | $150,921 | $163,148 | $234,131 | $215,776 | $172,980 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 | $0 |
| All other | $200 | $15,302 | $18,217 | $19,118 | $21,807 |
| Total | $778,831 | $1,188,786 | $1,606,289 | $1,689,514 | $948,789 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Acumen Pharmaceuticals, Inc. DEF 14A filed April 23, 2026, accession 0001628280-26-026870, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Acumen Pharmaceuticals, Inc. filed document, accession 0001628280-26-026870. Every figure is read from that document and cited to the page and table it appears in. Filed April 23, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 70,666 | $149,105 | — |
| RSU | 66,800 | $140,948 | — |
| RSU | 11,167 | $23,562 | — |
| Option | 3,125 | — | $5.19 |
| Option | 40,842 | — | $6.11 |
| Option | 82,813 | — | $4.23 |
| Option | 77,315 | — | $1.85 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Acumen Pharmaceuticals, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Acumen Pharmaceuticals’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Daniel O'Connell | Chief Executive Officer | $1,863,567 |
| Jim Doherty | President and Chief Development Officer | $1,012,859 |
| Matthew Zuga · this page | Chief Financial Officer and Chief Business Officer | $948,789 |
Matthew Zuga's compensation dossier, Acumen Pharmaceuticals
You have read Matthew Zuga's totals and holdings. The dossier adds each equity grant Acumen Pharmaceuticals disclosed for Matthew Zuga and Acumen Pharmaceuticals's own disclosed peer group, where the company discloses them, with every row in a PDF and a CSV cited to its filing.
See an example →The full Acumen Pharmaceuticals compensation record
free company briefThis page is one person within Acumen Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Acumen Pharmaceuticals's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Acumen Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Order ABOS
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.